New Dermatomyositis Treatment
FDA Approves First New Therapeutic Innovation in Decades for Adults With Dermatomyositis
Anonymous
The FDA has approved LISRAYA™ (brepocitinib) for adults with dermatomyositis, marking the first major breakthrough treatment for the rare autoimmune disease in decades GlobeNewswire. The once-daily pill directly targets key immune pathways that drive the condition, which causes muscle weakness and skin rashes. Patients can now access the drug through healthcare providers across the U.S., with some paying as little as $0 per month through the company's support program MarketScreener.
First New Treatment Option in Decades
Dermatomyositis is a debilitating systemic autoimmune disease that attacks muscles and skin DailyGuardian. Until now, treatment options for adults have remained limited. LISRAYA represents a major advance by offering a targeted approach to the underlying immune dysfunction. The drug comes in a 30 mg once-daily formulation, making it simple for patients to use MarketScreener.
Strong Trial Results Show Disease Improvement
LISRAYA demonstrated robust efficacy across multiple measures of disease activity in the largest dermatomyositis clinical trial ever conducted GlobeNewswire. The drug showed significant steroid-sparing benefits, meaning patients needed lower doses of corticosteroids to manage their symptoms. This is a major advantage, since long-term steroid use carries serious side effects including bone loss, infections, and weight gain Roivant.
Affordable Access Through Support Program
Roivant has launched the LISRAYA My Compass Support program to help patients afford the medication MarketScreener. Eligible patients can access the drug for as little as $0 per month, removing a major barrier to treatment. The program is available to all patients who can be prescribed LISRAYA by their healthcare provider, effective immediately GlobeNewswire.
Available Now for Prescription
Healthcare providers across the United States can now prescribe LISRAYA to adults with dermatomyositis GlobeNewswire. The drug is available for immediate dispensing through standard pharmacy channels. Patients should consult their doctor to determine if LISRAYA is appropriate for their specific condition and medical history DailyGuardian.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
4
Reach
5
Topics
A
AnonymousAuthor
